李增，教授，博士生導(dǎo)師

于2012年獲中山大學(xué)藥物化學(xué)博士學(xué)位，同年進(jìn)入安徽醫(yī)科大學(xué)工作至今。2018年至2019年度澳大利亞南澳大利亞大學(xué)訪問學(xué)者，2015年-2019年在安徽醫(yī)科大學(xué)藥學(xué)博士后流動(dòng)站工作。共發(fā)表包括Sci Transl Med、Eur J Med Chem、Bioorg Chem等在內(nèi)的SCI論文40余篇，申報(bào)中國(guó)發(fā)明專利16項(xiàng)，授權(quán)6項(xiàng)，實(shí)現(xiàn)專利成果轉(zhuǎn)化2項(xiàng)。主持完成國(guó)家自然科學(xué)基金青年項(xiàng)目、安徽省自然科學(xué)基金、安徽省高等學(xué)校自然科學(xué)研究項(xiàng)目等。主持企業(yè)橫向項(xiàng)目4項(xiàng)，已到賬經(jīng)費(fèi)達(dá)230余萬元。獲安徽省優(yōu)秀青年研究生導(dǎo)師、合肥市D類高層次人才、安徽醫(yī)科大學(xué)十佳教師等榮譽(yù)稱號(hào)

研究方向：新藥分子設(shè)計(jì)、合成及生物活性研究；合成生物蛋白的研發(fā)

電子郵箱：lizeng@ahmu.edu.cn

主持科研項(xiàng)目：

1.安徽省重點(diǎn)研究與開發(fā)計(jì)劃項(xiàng)目子課題.項(xiàng)目編號(hào)，2023z04020015；時(shí)間：20230701-20260630

2炎癥與免疫性疾病安徽省實(shí)驗(yàn)室人才支助計(jì)劃.項(xiàng)目編號(hào)，MMDL-PP0007；時(shí)間：2023201-20261230

3.安徽省自然科學(xué)基金面上項(xiàng)目.項(xiàng)目編號(hào)，2208085MH281；時(shí)間：20220101-20241231

4.安徽高校自然科學(xué)研究項(xiàng)目重大項(xiàng)目.項(xiàng)目編號(hào)，KJ2021ZD0019；時(shí)間：202201-202412

5.安徽省高校優(yōu)秀人才支持項(xiàng)目.項(xiàng)目編號(hào)，gxyq2020006；時(shí)間：202011-202211

6.安徽高校自然科學(xué)研究項(xiàng)目重點(diǎn)項(xiàng)目.項(xiàng)目編號(hào)，KJ2019A0231；時(shí)間：201907-202107

7.中國(guó)博士后科學(xué)基金項(xiàng)目.項(xiàng)目編號(hào)，2015M571916；時(shí)間，201507-201912

8.國(guó)家自然科學(xué)基金青年科學(xué)基金項(xiàng)目.項(xiàng)目編號(hào)，81302701；時(shí)間，201401-201612

9.安徽省自然科學(xué)基金青年基金項(xiàng)目.項(xiàng)目編號(hào)，1308085QC53；時(shí)間，201307-201506

近年來代表性論文：

1. Wang F, Ma J, Yang L, Hu P, Tang S, Wang J,Li Z*. Discovery of novel CXCR4 inhibitors for the treatment of inflammation by virtual screening and biological evaluation. Eur J Med Chem. 2024,275:116605.

2. Dong S, Xia J, Wang F, Yang L, Xing S, Du J, Zhang T,Zeng Li*. Discovery of novel deoxyvasicinone derivatives with benzenesulfonamide substituents as multifunctional agents against Alzheimer's disease. Eur J Med Chem. 2024,264:116013. 3. Jucheng Xia, Shuanghong Dong, Lili Yang, Fang Wang, Siqi Xing, Jiyu Du,Zeng Li*. Design, synthesis, and biological evaluation of novel tryptanthrin derivatives as selective acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2024, 143 ,106980.

4. Du J, Liu P, Zhu Y, Wang G, Xing S, Liu T, Xia J, Dong S, Lv N*, Li Z*. Novel tryptanthrin derivatives with benzenesulfonamide substituents: Design, synthesis, and anti-inflammatory evaluation. Eur J Med Chem. 2023,246:114956.

5. Zhang T, Xing S, Du J, Xia J, Dong S,Li Z*, Liu Z, Song Y. Discovery of novel TLR4/MD-2 inhibitors: Receptor structure-based virtual screening studies and anti-inflammatory evaluation. Bioorg Chem. 2023,141:106880.

6. Xing S, Fan W, Chen J, Du J, Liu T, Dong S, Xia J, Liu P, Zou D, Cai L,Li Z*. Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis. Eur J Med Chem. 2022;238:114497.

7. Wang JN#, Wang F#, Ke J#, Li Z#, Xu CH, Yang Q, Chen X, He XY, He Y, Suo XG, Li C, Yu JT, Jiang L, Ni WJ, Jin J, Liu MM, Shao W, Yang C, Gong Q, Chen HY, Li J, Wu YG, Meng XM. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms. Sci Transl Med. 2022,14(640):eabk2709.

8. Tongtong Liu, Shiming Chen, Jiyu Du, Siqi Xing, Rong Li,Zeng Li*. Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur J Med Chem. 2022 Jan 5;227:113973.